Larfix

Lornoxicam

Short-term treatment of mild to moderate pain associated w/ extra articular inflammation. Symptomatic treatment of pain & inflammation in OA & RA.

Individualized dosage. Acute pain 8-16 mg daily. OA & RA Initially 12 mg. All doses may be given in 2 or 3 divided doses. Max: 16 mg daily.

Should be taken on an empty stomach.

Hypersensitivity to lornoxicam & to other NSAIDs including acetylsalicylic acid. GI, cerebrovascular or other bleeding disorders; active or history of recurrent peptic ulceration; severe liver & renal impairment (serum creatinine >700 μmol/L); severe thrombocytopenia; severe heart insufficiency. Pregnancy & lactation. Patient <18 yr.

Discontinue if skin rash, mucosal lesions or any signs of hypersensitivity occur. Monitor renal function in patients who will undergo major surgery, cardiac failure, receiving diuretics or drugs able to cause kidney damage, in mild (serum creatinine 150-300 μmol/L) & moderate (serum creatinine 300-700 μmol/L) renal impairment. Discontinue if renal function deteriorates during treatment. Perform clinical monitoring & laboratory assessment in patients w/ blood coagulation disorders, hepatic impairment (eg, liver cirrhosis). Regularly assess Hb, creatinine & liver enzymes during long-term treatment (>3 mth). Increased risk of GI bleeding, ulceration & perforation in patients w/ history of ulcer or concomitant treatment w/ oral corticosteroids, anticoagulants (eg, warfarin), SSRIs, antiplatelet agents (eg, acetylsalicylic acid). Patients w/ history of GI toxicity; GI disease (ulcerative colitis, Crohn's disease); HTN &/or heart failure; bronchial asthma; SLE & mixed connective tissue disorders; increased bleeding disorders. Uncontrolled HTN, CHF, established ischaemic heart disease, peripheral arterial disease &/or cerebrovascular disease. Elderly >65 yr.

Abdominal pain, diarrhoea, dyspepsia, nausea, vomiting; dizziness, headache; increased BUN & creatinine levels; increased serum transaminase & alkaline phosphatase levels. Potentially, GI ulcerations w/ intestinal perforation (may be severe); duodenal ulcers, haematemesis, melaena; onset of severe skin reactions & serious life-threatening hypersensitivity reactions.

May enhance effect of anticoagulants (eg, warfarin). May decrease effect of phenprocoumon, loop, thiazide & K-sparing diuretics, ACE inhibitors, β-adrenergic blockers, angiotensin II receptor blockers. Decreased renal clearance of digoxin. Increased risk of GI bleeding w/ antiplatelet agents, SSRIs & other NSAIDs. Increased risk of GI bleeding & ulceration w/ corticosteroids. Increased risk of haematoma w/ heparin in the context of spinal or epidural anaesth. Increased risk of hypoglycemia w/ sulphonylureas (eg, glibenclamide). Increased risk of nephrotoxicity w/ tacrolimus. Increased serum conc of methotrexate, cyclosporine, lithium. Increased renal & GI toxicity & myelosuppression w/ pemetrexed. May have interactions w/ known CYP2C9 inducers & inhibitors.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AC05 - lornoxicam ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, oxicams.

POM